Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating

Amylyx Pharmaceuticals (NASDAQ:AMLX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also recently commented on AMLX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright upped their target price on shares of Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus assumed coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $21.00 target price for the company. Finally, Bank of America lifted their price target on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.56.

Amylyx Pharmaceuticals Stock Down 1.8%

AMLX opened at $13.85 on Friday. The stock has a market cap of $1.53 billion, a P/E ratio of -8.94 and a beta of -0.31. Amylyx Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $17.49. The company has a fifty day simple moving average of $13.94 and a 200 day simple moving average of $13.22.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. On average, equities research analysts expect that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 3,326 shares of Amylyx Pharmaceuticals stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the transaction, the chief financial officer owned 177,104 shares in the company, valued at $1,967,625.44. The trade was a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Justin B. Klee sold 1,995 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total value of $27,710.55. Following the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. The trade was a 0.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 151,203 shares of company stock valued at $2,028,385. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Commodore Capital LP acquired a new position in shares of Amylyx Pharmaceuticals in the third quarter worth approximately $55,386,000. First Light Asset Management LLC acquired a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at approximately $45,606,000. Adage Capital Partners GP L.L.C. raised its holdings in Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after purchasing an additional 3,102,395 shares during the last quarter. Millennium Management LLC raised its holdings in Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Amylyx Pharmaceuticals by 76.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock worth $53,992,000 after purchasing an additional 1,929,639 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals News Summary

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi‑year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer‑term upside.
• Positive Sentiment: Avexitide remains the company’s key near‑term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well‑funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near‑term profitability remains a multi‑quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near‑term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.